LIVIVO - Search results -

Search results

Result 1 - 10 of total 13

Search options

Article ; Online: Current therapies under investigation for COVID-19: potential COVID-19 treatments.

Weisberg, Ellen / Sattler, Martin / Yang, Priscilla L / Parent, Alexander / Gray, Nathanael / Griffin, James D

Canadian journal of physiology and pharmacology

2020 Volume 98, Issue 8, Page(s) 483–489

Abstract: ... treatments for COVID-19, the disease caused by SARS-CoV-2. ... antiviral agents/supportive therapy out of hundreds of drugs that are being repurposed or tested as potential ... researchers are expeditiously searching for antiviral treatments able to alleviate the symptoms of infection ...

Abstract	In response to the outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), researchers are expeditiously searching for antiviral treatments able to alleviate the symptoms of infection, which can be life-threatening. Here, we provide a general overview of what is currently known about the structure and characteristic features of SARS-CoV-2, some of which could potentially be exploited for the purposes of antiviral therapy and vaccine development. This minireview also covers selected and noteworthy antiviral agents/supportive therapy out of hundreds of drugs that are being repurposed or tested as potential treatments for COVID-19, the disease caused by SARS-CoV-2.
MeSH term(s)	Antiviral Agents/pharmacology ; Betacoronavirus/isolation & purification ; Betacoronavirus/pathogenicity ; Betacoronavirus/physiology ; Coronavirus Infections/drug therapy ; Coronavirus Infections/epidemiology ; Coronavirus Infections/therapy ; Humans ; Pandemics ; Pneumonia, Viral/epidemiology ; Pneumonia, Viral/therapy ; Therapies, Investigational/methods ; Treatment Outcome
Chemical Substances	Antiviral Agents
Keywords	covid19
Language	English
Publishing date	2020-07-08
Publishing country	Canada
Document type	Journal Article ; Review
ZDB-ID	127527-6
ISSN	1205-7541 ; 0008-4212
ISSN (online)	1205-7541
ISSN	0008-4212
DOI	10.1139/cjpp-2020-0286
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 589: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article: Current therapies under investigation for COVID-19: potential COVID-19 treatments

Weisberg, Ellen / Sattler, Martin / Yang, Priscilla L / Parent, Alexander / Gray, Nathanael / Griffin, James D

Can J Physiol Pharmacol

Abstract	In response to the outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), researchers are expeditiously searching for antiviral treatments able to alleviate the symptoms of infection, which can be life-threatening. Here, we provide a general overview of what is currently known about the structure and characteristic features of SARS-CoV-2, some of which could potentially be exploited for the purposes of antiviral therapy and vaccine development. This minireview also covers selected and noteworthy antiviral agents/supportive therapy out of hundreds of drugs that are being repurposed or tested as potential treatments for COVID-19, the disease caused by SARS-CoV-2.
Keywords	covid19
Publisher	WHO
Document type	Article
Note	WHO #Covidence: #636612
Database	COVID19

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Details ▾

Article: Therapeutic implications of current Janus kinase inhibitors as anti-COVID agents: A review.

Jain, Nem Kumar / Tailang, Mukul / Jain, Hemant Kumar / Chandrasekaran, Balakumar / Sahoo, Biswa Mohan / Subramanian, Anandhalakshmi / Thangavel, Neelaveni / Aldahish, Afaf / Chidambaram, Kumarappan / Alagusundaram, M / Kumar, Santosh / Selvam, Palani

Frontiers in pharmacology

2023 Volume 14, Page(s) 1135145

Abstract: ... as potential anti-COVID agents which opens up a new horizon in the treatment of COVID-19, effectively. ... of COVID-19 infection under different stages such as viral entry, escaping innate immunity, replication ... are required to understand the elaborated pathogenesis of COVID-19, duration of Jakinib treatment, and ...

Abstract	Severe cases of COVID-19 are characterized by hyperinflammation induced by cytokine storm, ARDS leading to multiorgan failure and death. JAK-STAT signaling has been implicated in immunopathogenesis of COVID-19 infection under different stages such as viral entry, escaping innate immunity, replication, and subsequent inflammatory processes. Prompted by this fact and prior utilization as an immunomodulatory agent for several autoimmune, allergic, and inflammatory conditions, Jakinibs have been recognized as validated small molecules targeting the rapid release of proinflammatory cytokines, primarily IL-6, and GM-CSF. Various clinical trials are under investigation to evaluate Jakinibs as potential candidates for treating COVID-19. Till date, there is only one small molecule Jakinib known as baricitinib has received FDA-approval as a standalone immunomodulatory agent in treating critical COVID-19 patients. Though various meta-analyses have confirmed and validated the safety and efficacy of Jakinibs, further studies are required to understand the elaborated pathogenesis of COVID-19, duration of Jakinib treatment, and assess the combination therapeutic strategies. In this review, we highlighted JAK-STAT signalling in the pathogenesis of COVID-19 and clinically approved Jakinibs. Moreover, this review described substantially the promising use of Jakinibs and discussed their limitations in the context of COVID-19 therapy. Hence, this review article provides a concise, yet significant insight into the therapeutic implications of Jakinibs as potential anti-COVID agents which opens up a new horizon in the treatment of COVID-19, effectively.
Language	English
Publishing date	2023-03-20
Publishing country	Switzerland
Document type	Journal Article ; Review
ZDB-ID	2587355-6
ISSN	1663-9812
ISSN	1663-9812
DOI	10.3389/fphar.2023.1135145
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Current Therapeutic Interventions for COVID-19

Hacer Efnan Melek ARSOY / Öner ÖZDEMİR

Bezmiâlem Science, Vol 8, Iss 3, Pp 105-

2020 Volume 116

Abstract: ... Although there are many drugs in the trial phase for COVID-19 treatment, the most promising and most effective ... such as prophylactic and supporting therapies, as well as care for critically ill patients and vaccine investigation ... of this disease, called coronavirus disease-19 (COVID-19), is variable, cytokine storm and different mechanisms ...

Abstract	Severe acute respiratory syndrome coronavirus-2 is an important infectious agent that was first detected in China, causing the pandemic and death of thousands of people. Although the clinic of this disease, called coronavirus disease-19 (COVID-19), is variable, cytokine storm and different mechanisms can cause increased mortality as a result of progressive and serious clinical presentations. Since it belongs to a well-known group of viruses, researchers have gained momentum after the isolation and the identification of the features of the virus. Although specific drugs began to be developed, the first potential candidate drugs were drugs such as broad-spectrum antibiotics, antiviral agents, anti-parasitic agents, and interferon, which were planned to be used with similar indications before pandemic. Trials on all steps such as prophylactic and supporting therapies, as well as care for critically ill patients and vaccine investigation studies are still ongoing. The drugs used in the light of the guidelines were frequently updated and some changes were made as a result of reports on side effects and efficacy evaluations. Especially in some drug combinations, side effects like prolonged QT interval, drug-drug interactions, and restrictions on the use of some drugs in the pediatric age group or pregnancy limit the specific, evidence-based and reliable treatment. Although there are many drugs in the trial phase for COVID-19 treatment, the most promising and most effective drugs are discussed and summarized under the light of national guidelines and clinical evidences with all aspects of the literature.
Keywords	sars-cov-2 ; 2019-ncov ; covid-19 ; drug treatment ; Medicine (General) ; R5-920
Subject code	610
Language	English
Publishing date	2020-12-01T00:00:00Z
Publisher	Galenos Publishing House
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Current therapies under investigation for COVID-19

Weisberg, Ellen / Sattler, Martin / Yang, Priscilla L. / Parent, Alexander / Gray, Nathanael / Griffin, James D.

Canadian Journal of Physiology and Pharmacology

potential COVID-19 treatments

2020 Volume 98, Issue 8, Page(s) 483–489

Abstract	In response to the outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), researchers are expeditiously searching for antiviral treatments able to alleviate the symptoms of infection, which can be life-threatening. Here, we provide a general overview of what is currently known about the structure and characteristic features of SARS-CoV-2, some of which could potentially be exploited for the purposes of antiviral therapy and vaccine development. This minireview also covers selected and noteworthy antiviral agents/supportive therapy out of hundreds of drugs that are being repurposed or tested as potential treatments for COVID-19, the disease caused by SARS-CoV-2.
Keywords	Physiology (medical) ; Physiology ; Pharmacology ; General Medicine ; covid19
Language	English
Publisher	Canadian Science Publishing
Publishing country	ca
Document type	Article ; Online
ZDB-ID	127527-6
ISSN	1205-7541 ; 0008-4212
ISSN (online)	1205-7541
ISSN	0008-4212
DOI	10.1139/cjpp-2020-0286
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

In stock of ZB MED Cologne/Königswinter

Zs.A 589: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Book ; Article ; Online: Current therapies under investigation for COVID-19

Weisberg, Ellen / Sattler, Martin / Yang, Priscilla L / Parent, Alexander / Gray, Nathanael / Griffin, James D

potential COVID-19 treatments

2020

Abstract: ... treatments for COVID-19, the disease caused by SARS-CoV-2. ... The accepted manuscript in pdf format is listed ... antiviral agents/supportive therapy out of hundreds of drugs that are being repurposed or tested as potential ...

Abstract	In response to the outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), researchers are expeditiously searching for antiviral treatments able to alleviate the symptoms of infection, which can be life-threatening. Here, we provide a general overview of what is currently known about the structure and characteristic features of SARS-CoV-2, some of which could potentially be exploited for the purposes of antiviral therapy and vaccine development. This minireview also covers selected and noteworthy antiviral agents/supportive therapy out of hundreds of drugs that are being repurposed or tested as potential treatments for COVID-19, the disease caused by SARS-CoV-2. The accepted manuscript in pdf format is listed with the files at the bottom of this page. The presentation of the authors' names and (or) special characters in the title of the manuscript may differ slightly between what is listed on this page and what is listed in the pdf file of the accepted manuscript; that in the pdf file of the accepted manuscript is what was submitted by the author.
Keywords	covid19
Subject code	302
Publishing date	2020-06-24
Publisher	NRC Research Press (a division of Canadian Science Publishing)
Publishing country	ca
Document type	Book ; Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: SARS-CoV-2 as an inflammatory cardiovascular disease: current knowledge and future challenges.

Shah, Kevin S / Hale Hammond, Mary Elizabeth / Drakos, Stavros G / Anderson, Jeffrey L / Fang, James C / Knowlton, Kirk U / Shaw, Robin M

Future cardiology

2021 Volume 17, Issue 7, Page(s) 1277–1291

Abstract: ... 19 and therapeutics under investigation. We discuss the potential long-term CV sequelae after ... SARS-CoV-2 is responsible for the 2020 global COVID-19 pandemic. In patients with COVID-19 ... recovery from COVID-19 and the gaps in knowledge including the pathophysiological links between acute ...

Abstract	SARS-CoV-2 is responsible for the 2020 global COVID-19 pandemic. In patients with COVID-19, multiple cardiovascular (CV) manifestations have been reported. SARS coronavirus 2 infection can lead to inflammatory CV disease first via takeover of the angiotensin-converting enzyme-2 enzyme as a cell receptor as well as the macrophage activation syndrome in severe illness. We review the CV manifestations of COVID-19 and therapeutics under investigation. We discuss the potential long-term CV sequelae after recovery from COVID-19 and the gaps in knowledge including the pathophysiological links between acute cardiac injury, myocardial inflammation and chronic cardiomyopathy. Future investigational efforts could result in significant diagnostic and therapeutic advances potentially impacting the broader field of chronic heart failure and cardiac recovery.
MeSH term(s)	COVID-19 ; Cardiovascular Diseases/epidemiology ; Cardiovascular Diseases/etiology ; Humans ; Myocarditis ; Pandemics ; SARS-CoV-2
Language	English
Publishing date	2021-03-19
Publishing country	England
Document type	Journal Article ; Review
ZDB-ID	2274267-0
ISSN	1744-8298 ; 1479-6678
ISSN (online)	1744-8298
ISSN	1479-6678
DOI	10.2217/fca-2020-0188
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 6836: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article: Current knowledge about the antivirals remdesivir (GS-5734) and GS-441524 as therapeutic options for coronaviruses

Amirian, E. Susan / Levy, Julie K.

One Health

Abstract: ... that is now being tested as a potential treatment for COVID-19 in international, multi-site ... the current coronavirus disease 2019 (COVID-19) pandemic has quickly intensified interest in developing ... therapeutic options that are under investigation. Thus, the purpose of this review is to synthesize ...

Abstract	Recent international epidemics of coronavirus-associated illnesses underscore the urgent medical and public health need for vaccine development and regulatory body approved therapies. In particular, the current coronavirus disease 2019 (COVID-19) pandemic has quickly intensified interest in developing treatment options to mitigate impact on human life. Remdesivir (GS-5734™) is a broad-spectrum antiviral drug that is now being tested as a potential treatment for COVID-19 in international, multi-site clinical trials. Currently available evidence about the antiviral effects of remdesivir against coronaviruses is primarily based on in vitro and in vivo studies (including some on a chemically related compound, GS-441524™), which have demonstrated largely favorable findings. As the pandemic progresses, information from human compassionate use cases will continue to accumulate before the clinical trials are concluded. It is imperative for public health practitioners and the One Health community to stay up to date on the most promising potential therapeutic options that are under investigation. Thus, the purpose of this review is to synthesize the knowledge to date about remdesivir as a therapeutic option for coronaviruses, with a special focus on information relevant to the One Health community.
Keywords	covid19
Publisher	WHO
Document type	Article
Note	WHO #Covidence: #17775
Database	COVID19

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Details ▾

Article: Current knowledge about the antivirals remdesivir (GS-5734) and GS-441524 as therapeutic options for coronaviruses

Amirian, E. Susan / Levy, Julie K

One health. 2020 June, v. 9

2020

Abstract	Recent international epidemics of coronavirus-associated illnesses underscore the urgent medical and public health need for vaccine development and regulatory body approved therapies. In particular, the current coronavirus disease 2019 (COVID-19) pandemic has quickly intensified interest in developing treatment options to mitigate impact on human life. Remdesivir (GS-5734™) is a broad-spectrum antiviral drug that is now being tested as a potential treatment for COVID-19 in international, multi-site clinical trials. Currently available evidence about the antiviral effects of remdesivir against coronaviruses is primarily based on in vitro and in vivo studies (including some on a chemically related compound, GS-441524™), which have demonstrated largely favorable findings. As the pandemic progresses, information from human compassionate use cases will continue to accumulate before the clinical trials are concluded. It is imperative for public health practitioners and the One Health community to stay up to date on the most promising potential therapeutic options that are under investigation. Thus, the purpose of this review is to synthesize the knowledge to date about remdesivir as a therapeutic option for coronaviruses, with a special focus on information relevant to the One Health community.
Keywords	COVID-19 infection ; Orthocoronavirinae ; antiviral agents ; humans ; pandemic ; public health ; therapeutics ; vaccine development
Language	English
Dates of publication	2020-06
Publishing place	Elsevier B.V.
Document type	Article
Note	NAL-AP-2-clean
ZDB-ID	2834831-X
ISSN	2352-7714
ISSN	2352-7714
DOI	10.1016/j.onehlt.2020.100128
Database	NAL-Catalogue (AGRICOLA)

Order via subito

Article ; Online: Current knowledge about the antivirals remdesivir (GS-5734) and GS-441524 as therapeutic options for coronaviruses

E. Susan Amirian / Julie K. Levy

One Health, Vol 9, Iss , Pp - (2020)

2020

Abstract	Recent international epidemics of coronavirus-associated illnesses underscore the urgent medical and public health need for vaccine development and regulatory body approved therapies. In particular, the current coronavirus disease 2019 (COVID-19) pandemic has quickly intensified interest in developing treatment options to mitigate impact on human life. Remdesivir (GS-5734™) is a broad-spectrum antiviral drug that is now being tested as a potential treatment for COVID-19 in international, multi-site clinical trials. Currently available evidence about the antiviral effects of remdesivir against coronaviruses is primarily based on in vitro and in vivo studies (including some on a chemically related compound, GS-441524™), which have demonstrated largely favorable findings. As the pandemic progresses, information from human compassionate use cases will continue to accumulate before the clinical trials are concluded. It is imperative for public health practitioners and the One Health community to stay up to date on the most promising potential therapeutic options that are under investigation. Thus, the purpose of this review is to synthesize the knowledge to date about remdesivir as a therapeutic option for coronaviruses, with a special focus on information relevant to the One Health community. Keywords: Remdesivir, GS-5734, Coronavirus, COVID-19, SARS-CoV-2, Compassionate use
Keywords	Medicine (General) ; R5-920 ; covid19
Subject code	306
Language	English
Publishing date	2020-06-01T00:00:00Z
Publisher	Elsevier
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Kategorien

Inter-library loan at ZB MED

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

Inter-library loan at ZB MED

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

Inter-library loan at ZB MED

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Kategorien

Inter-library loan at ZB MED

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

Inter-library loan at ZB MED